logo

For the Inventor, By the Inventor

Lexington, MA, United States of America

Dicerna Pharmaceuticals, Inc.


USPTO Granted Patents = 99



Trademarks = 7

Forward Citations = 353

Loading Chart...
Loading Chart...

43 inventors (with patents filed for the assignee):

goldMedal Bob Dale Brown (77 out of 92 patents)

silverMedal Henryk T Dudek (55 out of 60 patents)

bronzeMedal Marc Abrams (12 out of 12 patents)

4.  Cheng Lai (8 out of 8 patents)

5.  Weimin Wang (7 out of 7 patents)

6.  Utsav Saxena (6 out of 6 patents)

7.  Natalie Wayne Pursell (6 out of 6 patents)

8.  Naim Nazef (5 out of 5 patents)

9.  Shanthi Ganesh (5 out of 5 patents)

10.  Martin Koser (4 out of 4 patents)

11.  Jihye Park (4 out of 4 patents)

12.  Wen Han (4 out of 4 patents)

13.  Sujit Basu (3 out of 5 patents)

14.  Anton Turanov (3 out of 3 patents)

15.  Qingyi Li (2 out of 8 patents)


Core Competencies:
LPA Expression
APOC3 Expression
PNPLA3 Expression
Gene Expression Inhibition
Double-Stranded RNA
Nucleic Acid Inhibitors
Immunotherapy Potentiation
PCSK9 Targeting
Hepatitis B Treatment
Lactate Dehydrogenase Inhibition
Modified Oligonucleotides
Transmembrane Serine Protease 6

99 patents:

1. 12435336 - Compositions and methods for inhibiting LPA expression (2025-10-07),
2. 12252691 - Compositions and methods for inhibiting LPA expression (2025-03-18),
3. 12234456 - Compositions and methods for modulating APOC3 expression (2025-02-25),
4. 12084662 - Compositions and methods for modulating PNPLA3 expression (2024-09-10),
5. 12077756 - Extended dicer substrate agents and methods for the specific inhibition of gene expression (2024-09-03),
6. 12037586 - 4'-phosphate analogs and oligonucleotides comprising the same (2024-07-16),
7. 12037358 - Compositions comprising reversibly modified oligonucleotides and uses thereof (2024-07-16),
8. 11952574 - Compositions and methods for inhibiting transmembrane serine protease 6 (TMPRSS6) expression (2024-04-09),
9. 11912996 - Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA (2024-02-27),
10. 11873493 - Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA (2024-01-16),
11. 11873488 - Double-stranded nucleic acid inhibitor molecules modified with Tm-increasing nucleotides (2024-01-16),
12. 11851658 - Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA (2023-12-26),
13. 11813280 - Reducing beta-catenin and IDO expression to potentiate immunotherapy (2023-11-14),
14. 11773390 - Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNA (2023-10-03),
15. 11697812 - Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA (2023-07-11),
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapeutics. We are committed to leveraging our proprietary GalXC™ RNAi technology platform to develop innovative medicines for patients with rare diseases, liver diseases, cardiovascular diseases, and more.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
99 Patents

#9 in Lexington, MA

#206 in Massachusetts

#3,684 in US

#7,614 in the World

...
Lexington, MA, United States of America

Dicerna Pharmaceuticals, Inc.

Forward Citations = 353

43 inventors:

goldMedal Bob Dale Brown (77 out of 92 patents)

silverMedal Henryk T Dudek (55 out of 60 patents)

bronzeMedal Marc Abrams (12 out of 12 patents)

4.  Cheng Lai (8 out of 8 patents)

5.  Weimin Wang (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com
Loading…